Novel Breakthroughs in Management of Pediatric Low-Grade Glioma (pLGG) - Episode 2

Molecular Characterization of pLGG

Experts examine the molecular diversity of pediatric low-grade gliomas, exploring its significance for diagnostic approaches and therapeutic strategies.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Overview of pLGG presentation and categorization
    Now Viewing
    EP. 2: Molecular Characterization of pLGG
    EP. 3: Less Common Molecular Alterations in pLGG and Testing Recommendations
    EP. 4: Standard of care for frontline treatment of non-V600E-specific pLGG tumors
    EP. 5: Ongoing clinical trials for frontline treatment of non-V600E-specific pLGG tumors
    EP. 6: Current Treatment of Patients with NF1 pLGG
    EP. 7: Standard of Care Pptions Specific for Frontline Treatment of BRAF V600E-Mutated pLGG
    EP. 8: Treatment Considerations for Progressive pLGG
    EP. 9: Radiation and Targeted Therapies for Progressive pLGG
    EP. 10: The Role of Tovorafenib in Treatment of Progressive pLGG
    EP. 11: Clinical Trials to Increase Treatment Options in the Progressive Setting
    EP. 12: Clinical scenario 1 - BRAFKIAA-1549 fusion
    EP. 13: Alternatives and Considerations for Clinical Scenario 1
    EP. 14: Clinical Scenario 2 - BRAFV600E
    EP. 15: Potential Adverse Events With Targeted Therapies
    EP. 16: Clinical Insights: Looking Forward for pLGG
    1. Briefly describe the molecular heterogeneity of pLGG and its clinical implications for diagnosis and treatment
      • What is the role of molecular testing to inform pLGG treatment strategies?

    x